AMRI to develop and manufacture parenteral generics for Genovi

By Dan Stanton

- Last updated on GMT

AMRI to develop and manufacture parenteral generics for Genovi

Related tags Manufacturing Mass production

AMRI has won a contract to develop and manufacture five parenteral generic products for Genovi Pharmaceuticals.

The deal will see contract development and manufacturing organisation (CDMO) AMRI initially provide cGMP manufacture and analytical support for the registration of five of Genovi’s product candidates.

Last week AMRI shelled out $60m (€50m)​ for two Aptuit facilities – an aseptic manufacturing plant in Glasgow, UK, and an analytical chemistry services site in West Lafayette, Indiana – but spokesperson Gina Rothe said this announcement is unrelated to the acquisition.

“Although the two announcements are unrelated, we are excited about the ability to extend the benefits of our integrated service offering to new and existing customers for development, analytical services and commercial scale manufacturing of strategic and complex injectable products,”​ she told Outsourcing-Pharma.com.

Financial details were not disclosed, but AMRI will be reimbursed for technology transfer activities, analytical development and manufacture of regulatory submission batches, as well as receiving regulatory milestone payments. Under the terms of the deal, AMRI will supply Genovi with the products following regulatory approval.

Related news

Show more

Related products

show more

Understanding the hidden value of quality

Understanding the hidden value of quality

Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | Technical / White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Related suppliers

Follow us

Products

View more

Webinars